Long-Term Treatment of Depression with Antidepressants: A Systematic Narrative Review
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Objective: To examine the available scientific evidence for answers to clinically relevant questions on the effectiveness and tolerability of antidepressant drugs (ADs) for the long-term treatment of depression. Method: The Cochrane Library was searched up to July 2006. When no complete Cochrane review was available, we looked in PubMed for relevant systematic reviews or individual randomized controlled trials. Results: There was no good evidence that increasing the dosage of the initial AD is an effective strategy for patients with no, or partial, response to acute-phase treatment. There was no good evidence that switching between chemical classes of antidepressant was more effective than switching within a class. There was limited support from randomized trials for several augmentation strategies. There was good evidence for the effectiveness of long-term therapy to prevent relapse in patients who remitted after acute-phase treatment. The application of principles of evidence-based medicine suggested that thoughtful, individualized application of evidence is more appropriate than general statements. Conclusions: Available evidence provides some support for the effectiveness of several augmentation strategies in the management of patients with no, or partial, response to acute-phase treatment and for the individualized application of groupwise robust evidence for maintenance treatment with ADs to prevent relapses. However, side effects of these long-term treatments with ADs are poorly studied and reported.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 1×
“The STAR*D study directly informs this question because nonresponders to the open trial with citalopram (n = 727) were randomly allocated to sustained-release bupropion, sertraline, or extended-release venlafaxine.(21) The trial therefore compared a switch to an AD of the same class and a switch to a different class.”
MethodRelapse prevention with antidepressant drug treatment in depressive disorders: a systematic review
Geddes, J. R., Carney, S. M., Davies, C., Furukawa, T. A., Kupfer, D. J., Frank, E., & Goodwin, G. M. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12599-8 · Cited by 945 · cited 3×
“In this vignette, what is your predicted possibility of relapse within 1 year for this male patient? Well, it is of course hard to predict for certain, but he might be a typical patient represented in the systematic review by Geddes et al.(35) For example, in the Versiani et al(45) trial of reboxetine, the median numb…”
BackgroundResultInfluentialSelf-citationPrevention of Relapse following cognitive therapy vs medications in moderate to severe depression.
Hollon, S. D., DeRubeis, R. J., Shelton, R. C., Amsterdam, J. D., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Young, P. R., Haman, K. L., Freeman, B. B., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.417 · Cited by 735
Furukawa, T. A., Guyatt, G. H., & Griffith, L. E. (2002) · International Journal of Epidemiology · doi:10.1093/ije/31.1.72 · Cited by 318
Self-citationBollini, P., Pampaliona, S., Tibaldi, G., Kupelnick, B., & Munizza, C. (1999) · British Journal of Psychiatry · doi:10.1192/bjp.174.4.297 · Cited by 274
A double-blind, placebo-controlled study of antidepressant augementation with mirtazapine
Carpenter, L. L., Yasmin, S., & Price, L. H. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01262-8 · Cited by 244
Perahia, D. G., Gilaberte, I., Wang, F., Wiltse, C. G., Huckins, S. A., Clemens, J. W., Montgomery, S. A., Montejo, A. L., & Detke, M. J. (2006) · British Journal of Psychiatry · doi:10.1192/bjp.188.4.346 · Cited by 94
Extended-release venlafaxine in relapse prevention for patients with major depressive disorder
Simon, J. S., Aguiar, L. M., Kunz, N. R., & Lei, D. (2004) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2003.10.004 · Cited by 69
Cited by
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Kato, M., Hori, H., Inoue, T., Iga, J., Iwata, M., Inagaki, T., Shinohara, K., Imai, H., Murata, A., Mishima, K., et al. (2021) · Molecular Psychiatry · doi:10.1038/s41380-020-0843-0 · Cited by 152
Discontinuation of psychotropic medication: a synthesis of evidence across medication classes.
Vinkers, C. H., Kupka, R. W., Penninx, B. W., Ruhé, H. G., van Gaalen, J. M., van Haaren, P. C. F., Schellekens, A. F. A., Jauhar, S., Ramos-Quiroga, J. A., Vieta, E., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02445-4 · Cited by 51
Shinohara, K., Efthimiou, O., Ostinelli, E. G., Tomlinson, A., Geddes, J. R., Nierenberg, A. A., Ruhe, H. G., Furukawa, T. A., & Cipriani, A. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027574 · Cited by 27
Self-citationStrategic use of new generation antidepressants for depression: SUN(^_^)D study protocol
Furukawa, T. A., Akechi, T., Shimodera, S., Yamada, M., Miki, K., Watanabe, N., Inagaki, M., & Yonemoto, N. (2011) · Trials · doi:10.1186/1745-6215-12-116 · Cited by 23
Self-citation
Metadata
- Authors
- Furukawa, T. A., Cipriani, A., Barbui, C., & Geddes, J. R.
- Venue
- The Canadian Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2007-09
- Volume
- 52
- Issue
- 9
- Pages
- 545-552
- ISSN
- 0706-7437 (ISSN-L)
- 1497-0015
- OpenAlex
- W131844925
- Cited by
- 33
- References
- 8
- FWCI
- 0.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.